No Data
No Data
Xinrui Pharmaceutical (06108.HK) signed a cornerstone investment agreement with Jiangxi Yimai Sunshine Group
Gelonghui, May 30, 丨 Xinrui Pharmaceutical (06108.HK) announced that on May 28, 2024, China Xinrui (a wholly-owned subsidiary of the company, as an investor) signed a cornerstone investment agreement with Jiangxi Yimai Sunshine Group, CITIC Securities (Hong Kong) Limited (as the sole sponsor) and CITIC Lyon Securities Limited (as the sole sponsor and overall coordinator). Based on this, China Xinrui has agreed to subscribe for investors' shares at the sale price. The total investment in investors' shares is HK$12 million (excluding brokerage commissions and levies that China Emerging Companies will pay on investors' shares).
Yimai Sunshine (02522.HK) is expected to go public on June 7 and introduce cornerstones such as Lianying Medical
Gelonghui, May 30, 丨 Yimai Sunshine (02522.HK) announced that the company plans to sell 178.16 million shares globally, 1.782 million shares in Hong Kong, China, and 16.34 million shares; the expected pricing date is June 5 from May 30 to June 4, 2024; the sale price will be HK$14.60-16.80 per share, with 500 shares per lot; CITIC Securities is the sole sponsor; it is expected that the shares will start trading on the main board of the Stock Exchange on June 7, 2024. The company is a leading medical imaging specialist medical group in China.
Xinrui Pharmaceutical (06108) subsidiary plans to increase capital injection into Shengzhou Xinrui Wanlin enterprise management
Xinrui Pharmaceutical (06108) issued an announcement. On May 24, 2024, Zhejiang, an indirect wholly-owned subsidiary of the company...
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
New Ray Medicine International Unit to Buy 16% Stake in Pharmaceutical Firm
New Ray Medicine International Holding (HKG:6108) unit Major Bright Holdings will buy a 16% stake in China Nvwa Pharmaceutical Group from an individual third party for around HK$17.3 million, a Thursd
A subsidiary of Xinrui Pharmaceutical plans to acquire 16% of the issued share capital of China Nu Wa Pharmaceutical Group
Xinrui Pharmaceuticals (06108) announced that on May 16, 2024 (after the trading period), the buyer Major Bright Holdings Limited (an indirect wholly-owned subsidiary of the company) entered into a sales agreement with the seller Yu Wenyong (as an independent third party). According to this, the seller conditionally agreed to sell and the buyer conditionally agreed to purchase shares for sale at a cost of HK$17.28 million. Shares for sale account for 16% of the issued share capital of the target company China Nu Wa Pharmaceutical Group Co., Ltd. The target group is mainly engaged in the manufacture, sale and distribution of pharmaceutical products in China. The announcement stated,
No Data